Literature DB >> 32757248

Gender differences in cutaneous melanoma: Demographics, prognostic factors, and survival outcomes.

Sara Behbahani1, Spandana Maddukuri1, Joshua B Cadwell1, W Clark Lambert1, Robert A Schwartz1.   

Abstract

Several recent studies have reported a considerably higher overall survival (OS) rate in females in various geographic regions This study further investigates the characteristics of melanoma that contribute to OS of women residing in the United States. Chi-square, Kaplan-Meier, and Cox regression models were used to analyze differences in demographics, treatment, and survival of invasive cutaneous melanoma in men and women diagnosed from 2004 to 2016 in the National cancer database. In 316 966 patients met inclusion criteria. Men had a significantly higher median age of diagnosis at 61 years (interquartile range or IQR: 51-72) in comparison to women where the median age of diagnosis was 55 years (IQR: 43-68) (P < .0001). The most common primary site for men was the trunk (35.5%), whereas the lower extremities were the most common primary site for women (30.3%). Women had a higher 5 year (82.6%) and 10 year (73.1%) OS compared to 5 year and 10 year OS of 72.2% and 58.7%, respectively, in men (P < .0001). When adjusting for confounders, female gender was independently associated with improved OS (ref: male HR = 0.791; 95% confidence interval 0.773-0.809; P < .0001). Overall, we conclude that female gender is an independent favorable prognostic factor for melanoma survival.
© 2020 Wiley Periodicals LLC.

Entities:  

Keywords:  gender; melanoma; prognosis

Mesh:

Year:  2020        PMID: 32757248     DOI: 10.1111/dth.14131

Source DB:  PubMed          Journal:  Dermatol Ther        ISSN: 1396-0296            Impact factor:   2.851


  5 in total

1.  Focused Information Criterion for Restricted Mean Survival Times: Non-Parametric or Parametric Estimators.

Authors:  Szilárd Nemes; Andreas Gustavsson; Alexandra Jauhiainen
Journal:  Entropy (Basel)       Date:  2022-05-16       Impact factor: 2.738

2.  Effects of COVID-19 Lockdown on Melanoma Diagnosis in Switzerland: Increased Tumor Thickness in Elderly Females and Shift towards Stage IV Melanoma during Lockdown.

Authors:  Lisa Kostner; Sara Elisa Cerminara; Gustavo Santo Pedro Pamplona; Julia-Tatjana Maul; Reinhard Dummer; Egle Ramelyte; Johanna Mangana; Nikolaus Benjamin Wagner; Antonio Cozzio; Saskia Kreiter; Angelika Kogler; Markus Streit; Anja Wysocki; Alfred Zippelius; Heinz Läubli; Alexander Andreas Navarini; Lara Valeska Maul
Journal:  Cancers (Basel)       Date:  2022-05-10       Impact factor: 6.575

Review 3.  Sex Differences in Cutaneous Melanoma: Incidence, Clinicopathological Profile, Survival, and Costs.

Authors:  Alessandra Buja; Massimo Rugge; Giovanni Damiani; Manuel Zorzi; Chiara De Toni; Antonella Vecchiato; Paolo Del Fiore; Romina Spina; Vincenzo Baldo; Alessandra Rosalba Brazzale; Carlo Riccardo Rossi; Simone Mocellin
Journal:  J Womens Health (Larchmt)       Date:  2022-01-25       Impact factor: 3.017

4.  Investigating Serum and Tissue Expression Identified a Cytokine/Chemokine Signature as a Highly Effective Melanoma Marker.

Authors:  Marco Cesati; Francesca Scatozza; Daniela D'Arcangelo; Gian Carlo Antonini-Cappellini; Stefania Rossi; Claudio Tabolacci; Maurizio Nudo; Enzo Palese; Luigi Lembo; Giovanni Di Lella; Francesco Facchiano; Antonio Facchiano
Journal:  Cancers (Basel)       Date:  2020-12-08       Impact factor: 6.639

5.  Spending and Hospital Stay for Melanoma in Hunan, China.

Authors:  Xinchen Ke; Wenrui Lin; Daishi Li; Shuang Zhao; Mingliang Chen; Yi Xiao; Xiang Chen; Minxue Shen; Juan Su
Journal:  Front Public Health       Date:  2022-07-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.